Scale-up and Translation of Extracellular Vesicle Therapeutics for Regenerative Medicine (U43/U44)
This FOA uses SBIR U43/U44 cooperative agreements to fund development of platform technologies for producing, manufacturing, and translating native or engineered extracellular vesicle (EV) therapeutics for regenerative medicine. Projects should focus on scale-up, analytical methods, manufacturing processes, and preclinical translation; clinical trials are not allowed under this announcement.
This FOA provides support using the SBIR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repai…
Funding Source
Awards & funding
Eligibility
Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.S…
Supporting links
Documents
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers